Autologous Mesenchymal Stem Cell Transplantation in Liver Cirrhosis

Saglik Bilimleri Universitesi Gulhane Tip Fakultesi25 enrolled

Overview

This study is aiming to investigate the efficacy of autologous mesenchymal stem cell (MSC) transplantation in 25 randomized patients with liver cirrhosis autologous mesenchymal stem cell will be derived from patients' bone marrows and will be infused via peripheral vein. Liver biopsies will be performed in every patient in the beginning and at 6th month.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Liver Cirrhosis

Interventions

autologous mesenchymal stem cell transplantationGENETIC

Every patient is given 1x106 MSCs per kg infused via peripheral vein.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * radiological, clinical and histopathological diagnosis of liver cirrhosis * absence of hepatocellular carcinoma or any malignancies * no psychiatric disorder * no serous cardiovascular and pulmonary comorbidities * serum total bilirubin levels less than 5 mg/dL * platelet counts more than 30.000 mm3 * more than one year follow up period after initiation of antiviral drugs Exclusion Criteria: * alcohol intake in last one year * initiation of antiviral medication in last one year * systemic diseases

Locations (1)

Gulhane Military Medical Academy Department of Gastroenterology

Ankara, Turkey (Türkiye)

Outcomes

Primary Outcomes

clinical improvement

biochemical and hematologic parameters

Time frame: clinical improvement parameters will be assessed six month after mesenchymal stem cell transplantation

Secondary Outcomes

liver regeneration

histopathologic assesments comparing before and at 6th month liver biopsies

Time frame: 6.th month after MSC transplantation

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.